Quantcast

Latest Addrenex Pharmaceuticals Stories

2008-10-24 09:00:07

Addrenex Pharmaceuticals has announced that the FDA has approved its investigational new drug application for ADX415, a novel hypertension drug. With the approval, Addrenex has launched a Phase II clinical trial to study ADX415 as a targeted therapy for hypertension. The Phase II trial is a multicenter, double-blind, placebo-controlled, dose-ranging study that will involve 80 patients. ADX415 is a novel, patented, centrally acting, alpha-adrenergic receptor agonist specific to alpha-2...

2008-09-11 12:00:43

Sciele Pharma and Addrenex Pharmaceuticals have announced that the preliminary analysis of the Phase III clinical study investigating the use of Clonicel for the treatment of attention deficit hyperactivity disorder has shown statistically significant improvement over placebo. The study has indicated that Clonicel achieved statistical significance on the primary endpoint, which is based on the attention deficit hyperactivity disorder (ADHD) rating scale of 18 symptoms developed by the...

2008-09-10 18:00:08

DURHAM, N.C., Sept. 10 /PRNewswire/ -- A drug that diminishes the body's hyper-reactivity to stress has been shown to significantly reduce symptoms of attention-deficit hyperactivity disorder (ADHD) in children, according to a phase 3 clinical trial conducted by Addrenex Pharmaceuticals. The study showed that the new drug, Clonicel, achieved statistically significant improvement over placebo in reducing an aggregate of 18 ADHD symptoms listed by the American Psychiatric Association and...

2008-09-10 15:00:07

Sciele Pharma, Inc. (NASDAQ:SCRX) and Addrenex Pharmaceuticals today announced that the preliminary analysis of the Phase III clinical study investigating the use of Clonicel(R) for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) showed statistically significant improvement over placebo. The study indicated that Clonicel achieved statistical significance on the primary endpoint, which is based on the ADHD Rating Scale of 18 symptoms developed by the American Psychiatric...

2008-08-19 15:01:22

DURHAM, N.C., Aug. 19 /PRNewswire/ -- Addrenex Pharmaceuticals ( http://www.addrenex.com/ ) has made three strategic hires this month to further its goal of identifying and developing as many new drug candidates as possible over the next 18 months. The fast-paced timeline they have set for drug discovery mirrors the company's recent successes in developing two new drugs, Clonicel(R) for attention deficit/hyperactivity disorder and CloniBID for hypertension, over the past two years. A new...

2008-07-01 18:00:29

DURHAM, N.C., July 1 /PRNewswire/ -- Two years after Addrenex Pharmaceuticals set it sights on building a new class of drugs to regulate "adrenergic excess," the small Durham company has signed its second major deal with Sciele Pharma, this time to co-develop a new compound for hypertension and other potential indications. Adrenalin is well known as the hormone that triggers the "fight or flight" reaction in response stress or danger. But Addrenex scientists recognized this hormone, and...


Word of the Day
omphalos
  • The navel or umbilicus.
  • In Greek archaeology: A central boss, as on a shield, a bowl, etc.
  • A sacred stone in the temple of Apollo at Delphi, believed by the Greeks to mark the 'navel' or exact center-point of the earth.
'Omphalos' comes from the ancient Greek.
Related